Affimed's second VC round to fund cancer programs

Germany's Affimed Therapeutics raised $32 million in its second round. Much of that money will be used to finance the clinical development of its leading programs for Hodgkin's disease and non-Hodgkin's Lymphoma. Affimed also plans to advance additional pre-clinical antibody programs in various other oncology and anti-inflammatory indications. BioMedInvest, OrbiMed Advisors and Life Sciences Partners all participated in the consortium.

"Attracting these top-tier international investors represents a strong validation of Affimed's unique and highly versatile alternative approach to conventional antibody technologies as well as its advanced product pipeline. We are now in an excellent position to advance the clinical development of our lead antibodies into Phase II for the treatment of cancer," said Rolf H. Guther, MD PhD, CEO of Affimed.

- see the release for more information

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.